



### Downscale finite element modeling of aortic valve leaflets for *in situ* estimation of cell level mechanics

### Rachel Buchanan, Rong Fan, and Michael Sacks



Excerpt from the Proceedings of the 2012 COMSOL Conference in Boston

### **Heart Valve Function** A multi-scale biomechanical problem



GAGs

# The Valve Interstitial Cell

- Mixed fibroblast & smooth-muscle cell phenotype
- Active communicating cell-cell junctions
- Highly "reactive" and contractile
- Maintain the valve ECM homeostasis through protein synthesis and enzyme degradation
- Quiescent during homeostasis & active during growth and disease

#### Cell-Cell junctions connecting 2 AVICs



### VIC-ECM Coupling: Role in force generation

- VICs align in parallel with the collagen fiber preferred direction
- Integrin mediated contraction/force generation<sup>1</sup>





# VIC Stiffness/Contraction

- Decoupling of stiffness and contraction
- VICs balance forces via contraction to maintain valve homeostasis
- Role of VIC contraction in valve function is poorly understood
- <u>Contraction effects</u>:

<u>Short Term</u>  $\rightarrow$  Increased stiffness

 $\underline{\text{Long Term}} \rightarrow \text{Activation of}$ mechanochemical signaling



External Stress  $\rightarrow$  Contraction  $\rightarrow$  Increased cell stiffness  $\rightarrow$  Mechanotransduction

## Mechanotransduction



- Increased transvalvular pressure positively correlates with higher effective stiffness in VICs<sup>1</sup>
- Strong relation of SMA and HSP47 indicating VICs response to mechanical stimuli in an attempt to maintain valve homeostasis
- Similar trends were found in *in situ* studies

<sup>1</sup>Merryman, W.D., et al., American Journal of Physiology-Heart and Circulatory Physiology, 2006.

### Limitations of Ex-vivo methods Discrepancy greater than 100-fold<sup>1,2</sup>

• Proportional changes consistent, yet vary in magnitude



<sup>1</sup>Merryman, W.D., et al., American Journal of Physiology-Heart and Circulatory Physiology, 2006. <sup>2</sup>Merryman, W.D., et al., Tissue Engineering, 2007.

# Goals

 Develop an integrated computational-experimental tool to assess AVIC physical state in the *in situ* environment (low and high force regions)

• Ultimately a true multi-scale model based on highfidelity 3D tissue micromorphology

• Accurately address layer and regional differences (belly region, coaptation, commissure, basal attachment)

### Current experimental methods: Flexure testing<sup>1</sup>

- Physiologically relevant deformation
- Low force measurements in situ
- Probe transmural effects





<sup>1</sup>Merryman, W.D., et al.,. Journal of Biomechanics, 2006



# **Flexure Experimental Results**

Bi-directional linearity of M vs.  $\Delta k^1$  suggest linear material model





<sup>1</sup>Merryman, W.D., et al., Journal of Biomechanics, 2006

#### Averaged Specimen Data



### Isotropic Hyperelastic Material Model

• Bimodular Ogden (N=1):

$$W^{\pm} = \frac{\mu^{\pm}}{\alpha} \left( \lambda_1^{\alpha} + \lambda_2^{\alpha} + \lambda_3^{\alpha} - 3 \right)$$

• Incompressibility Assumption:

$$W^{\pm} = \frac{\mu^{\pm}}{\alpha} (\lambda_1^{\alpha} + \lambda_2^{\alpha} + \lambda_1^{-\alpha} \lambda_2^{-\alpha} - 3)$$

• When  $\alpha$ = 2 becomes a Bimodular Neo-Hookean material model

$$W^{\pm} = \frac{\mu^{\pm}}{2} (\lambda_1^2 + \lambda_2^2 + \lambda_1^{-2} \lambda_2^{-2} - 3)$$



-0.06



## **Comsol Model Details**



- Isotropic incompressible hyperelastic model
- 4 assigned shear moduli (bilayer/bimodular)
  - $\mu_{Fibrosa}^{+/-}$   $\mu_{Venticularis}^{+/-}$
  - Stiffer in compression similar to bending of rubber
- Brick element mesh
- Study Extension (Continuation)
- Direct Solver

# Justification/Uniqueness

1. Neo-Hookean Bilayer

-captures thapsigargin state only

-unable to capture the M/I vs. curvature relation (normal and hyper

-unable to capture the bidirectionality

2. Ogden Bilayer

-captures the M/I vs. curvature relation for all 3 states -unable to capture the bidirectionality

### 3. Ogden Bilayer / Bimodular

-captures the M/I vs. curvature relation and bidirectionality for all 3 states

# Results



#### **Normal Basal Tonus**



#### Hypertensive





### Ogden Bilayer/Bimodular/Bidirectional

$$W^{\pm} = \frac{\mu^{\pm}}{\alpha} (\lambda_1^{\alpha} + \lambda_2^{\alpha} + \lambda_1^{-\alpha} \lambda_2^{-\alpha} - 3)$$

Thapsigargin	µ⁺ (kPa)	μ⁻(kPa)
F	40	60
V	30	40

Normal Basal Tonus	μ+ (kPa)	μ⁻ (kPa)
F	250	350
V	40	200

Hypertensive	µ⁺ (kPa)	µ⁻ (kPa)
F	300	400
V	40	300

α= 1.5

### Model Coupling



→



### First-order computational homogenization method

- Localization: Macro scale displacements (F<sub>M</sub>) mapped to the boundary nodes of the RVEs
- <u>Homogenization</u>: Classical 1<sup>st</sup> order homogenization procedure (average stress over RVE)

$$\overline{\sigma} = \frac{1}{V} \int \sigma(\hat{x}) dV$$

 Becomes the baseline stress value of the "homogeneous" tissue



<sup>1</sup>Kouznetsova, V.G. "Computational homogenization for the multi-scale analysis of multi-phase materials".Ph.D. dissertation, Technische Universiteit Eindhoven, 2002.

### Determine cell stiffness contribution



### Influence of ECM and Cell Stiffness on Tissue Properties



# **3D** micromorphology Integration

• Developing a more realistic model that incorporates recent micromorphology data relating to layer varying properties



### Combining flexure and low level stretch

Physiologically relevant testing capable of investigating **small level** forces that represent residual stresses known to be present<sup>1</sup>



<sup>1</sup>Amini, R, et al., Annals of Biomedical Engineering, 2012.

# Conclusions

- Multi-scale approaches can provide a sensitive method to estimate individual cell behavior *in situ* from tissue level measurements
- A bilayer/bimodular hyperelastic model is essential to capture bidirectional effects of tissue response
- Expand existing models to reflect true regional micromorphology of the valve
- Account for full physiological loading conditions
- Use as an investigative tool for VIC state with various agents (e.g. statins).

# Acknowledgements

<u>Funding</u>
NIH R01 HL-068816 and HL-089750

### Thank you!

